Home / OKUR : NASDAQ

AI Analysis Fundamentals Valuation Video Analysis News Similar

AI Analysis

How does OKUR make money? Does OKUR have pricing power? What's the Earnings Whisper? Will OKUR profit more as the business scales? What is OKUR's management track record? Is OKUR's current price justified?

OnKure Therapeutics, Inc.

$3 +$0.04 (+1.35%)

NASDAQ · 14 Sep 2026 20:00 UTC

Previous Close

$3.1

Day Range

$2.97$3.14

Year Range

$2.23$5.38

Market Cap

121.49M

AVG Volume

256.85K

Trailing/Forward PE

-0.86/-

PEG ratio

0.05

Dividend Yield

Next Earnings Date

2026-11-05

Primary Exchange

NASDAQ

Net Income (USD) · TTM

OKUR Net Income (USD) · TTM by quarter
Period	Net Income (USD) · TTM
26 Q2	-58.7M
26 Q1	-58.75M
25 Q4	-59.52M
25 Q3	-81.21M
25 Q2	-70.2M
25 Q1	-68.95M
24 Q4	-62.56M
24 Q3	-8.84M
24 Q2	-24.35M
24 Q1	-18.39M

Operating Income (USD) · TTM

OKUR Operating Income (USD) · TTM by quarter
Period	Operating Income (USD) · TTM
26 Q2	-62.14M
26 Q1	-61.56M
25 Q4	-62.95M
25 Q3	-82.62M
25 Q2	-71.79M
25 Q1	-69.81M
24 Q4	-62.64M
24 Q3	-7.73M
24 Q2	-23.76M
24 Q1	-18.05M

EBITDA (USD) · TTM

OKUR EBITDA (USD) · TTM by quarter
Period	EBITDA (USD) · TTM
26 Q2	-58.09M
26 Q1	-57.92M
25 Q4	-58.68M
25 Q3	-76.54M
25 Q2	-65.73M
25 Q1	-64.52M
24 Q4	-58.19M
24 Q3	-8.07M
24 Q2	-23.55M
24 Q1	-17.61M

Cash Flows (USD) · TTM

OKUR Cash Flows (USD) · TTM by quarter
Period	Cash Flows (USD) · TTM
26 Q2	-47.86M
26 Q1	-50.79M
25 Q4	-51.87M
25 Q3	-61.42M
25 Q2	-59.05M
25 Q1	-52.25M
24 Q4	-48.87M
24 Q3	-18.47M
24 Q2	-26.57M
24 Q1	-31.24M

EPS (USD) · TTM

OKUR EPS (USD) · TTM by quarter
Period	EPS (USD) · TTM
26 Q2	-3.5
26 Q1	-4.33
25 Q4	-4.41
25 Q3	-6.06
25 Q2	-5.25
25 Q1	-5.17
24 Q4	-4.69
24 Q3	-0.66
24 Q2	-1.82
24 Q1	-1.37

Expenses (USD) · TTM

OKUR Expenses (USD) · TTM by quarter
Period	Expenses (USD) · TTM
26 Q2	62.16M
26 Q1	61.6M
25 Q4	63M
25 Q3	82.71M
25 Q2	71.88M
25 Q1	69.89M
24 Q4	62.72M
24 Q3	7.81M
24 Q2	23.8M
24 Q1	18.14M

Shares Outstanding (USD) · TTM

OKUR Shares Outstanding (USD) · TTM by quarter
Period	Shares Outstanding (USD) · TTM
26 Q2	-1.73M
26 Q1	-11.67M
25 Q4	-11.63M
25 Q3	-10.25M
25 Q2	-7.37M
25 Q1	-6.27M
24 Q4	-3.63M
24 Q3	1.6M
24 Q2	1.67M
24 Q1	3.47M

Employee Count

OKUR Employee Count by quarter
Period	Employee Count
2025	45
2024	46
2023	8
2022	36
2021	20

Free Cash Flow Yield

OKUR Free Cash Flow Yield by quarter
Period	Free Cash Flow Yield
Sep 26	-30.96%
Sep 26	-26.81%
Aug 26	-25.32%
Aug 26	-24.36%
Aug 26	-24.05%
Aug 26	-23.18%
Jul 26	-97.24%
Jul 26	-90.16%
Jul 26	-88.44%
Jul 26	-86.79%
Jul 26	-81.1%
Jun 26	-82.54%
Jun 26	-82.91%
Jun 26	-88.44%
Jun 26	-88.65%
May 26	-88.44%
May 26	-88.23%
May 26	-117.55%
May 26	-95%
May 26	-81.14%
Apr 26	-79.96%
Apr 26	-76.76%
Apr 26	-89.26%
Apr 26	-89.46%
Mar 26	-96.19%
Mar 26	-91.6%
Mar 26	-101.53%
Mar 26	-149.06%
Feb 26	-167.76%
Feb 26	-174.86%
Feb 26	-187.87%
Feb 26	-181.86%
Jan 26	-172.21%
Jan 26	-155.17%
Jan 26	-151.55%
Jan 26	-144.79%
Jan 26	-153.6%
Dec 25	-162.37%
Dec 25	-151.04%
Dec 25	-148.09%
Dec 25	-148.58%
Nov 25	-151.04%
Nov 25	-176.22%
Nov 25	-145.25%
Nov 25	-154.64%
Oct 25	-128.95%
Oct 25	-131.67%
Oct 25	-157.25%
Oct 25	-143.33%
Oct 25	-161.31%
Sep 25	-174.16%
Sep 25	-170.09%
Sep 25	-178.43%
Sep 25	-158.96%
Aug 25	-158.96%
Aug 25	-154.47%
Aug 25	-172.78%
Aug 25	-190.79%
Aug 25	-176.92%
Jul 25	-168.49%
Jul 25	-167.05%
Jul 25	-155.69%
Jul 25	-163.54%
Jun 25	-162.17%
Jun 25	-164.23%
Jun 25	-146.87%
Jun 25	-135.15%
May 25	-153.84%
May 25	-181.03%
May 25	-194.61%
May 25	-202.72%
May 25	-146.53%
Apr 25	-140.89%
Apr 25	-126.75%
Apr 25	-124.18%
Apr 25	-117.04%
Mar 25	-82.13%
Mar 25	-72.54%
Mar 25	-79.46%
Mar 25	-72.97%
Feb 25	-27.31%
Feb 25	-25.36%
Feb 25	-24.12%
Feb 25	-23.66%
Jan 25	-22.51%
Jan 25	-24.46%
Jan 25	-23.91%
Jan 25	-18.63%
Jan 25	-15.43%
Dec 24	-16.97%
Dec 24	-16.52%
Dec 24	-14.04%
Dec 24	-9.78%
Nov 24	-8.98%
Nov 24	-12.81%
Nov 24	-12%
Nov 24	-11.33%
Nov 24	-12.23%
Oct 24	-11.7%
Oct 24	-10.76%

Price to Book

OKUR Price to Book by quarter
Period	Price to Book
Sep 26	0.9
Sep 26	1.04
Aug 26	1.1
Aug 26	1.14
Aug 26	1.16
Aug 26	1.2
Jul 26	0.28
Jul 26	0.31
Jul 26	0.31
Jul 26	0.32
Jul 26	0.34
Jun 26	0.33
Jun 26	0.33
Jun 26	0.31
Jun 26	0.31
May 26	0.31
May 26	0.31
May 26	0.23
May 26	0.29
May 26	1.14
Apr 26	1.15
Apr 26	1.2
Apr 26	1.03
Apr 26	1.03
Mar 26	0.96
Mar 26	1.01
Mar 26	0.91
Mar 26	0.62
Feb 26	0.55
Feb 26	0.53
Feb 26	0.49
Feb 26	0.51
Jan 26	0.54
Jan 26	0.6
Jan 26	0.61
Jan 26	0.64
Jan 26	0.6
Dec 25	0.57
Dec 25	0.61
Dec 25	0.62
Dec 25	0.62
Nov 25	0.61
Nov 25	0.52
Nov 25	0.64
Nov 25	0.6
Oct 25	0.59
Oct 25	0.57
Oct 25	0.48
Oct 25	0.53
Oct 25	0.47
Sep 25	0.43
Sep 25	0.44
Sep 25	0.42
Sep 25	0.48
Aug 25	0.48
Aug 25	0.49
Aug 25	0.44
Aug 25	0.3
Aug 25	0.33
Jul 25	0.34
Jul 25	0.35
Jul 25	0.37
Jul 25	0.35
Jun 25	0.36
Jun 25	0.35
Jun 25	0.39
Jun 25	0.43
May 25	0.37
May 25	0.32
May 25	0.3
May 25	0.28
May 25	0.32
Apr 25	0.33
Apr 25	0.37
Apr 25	0.38
Apr 25	0.4
Mar 25	0.57
Mar 25	0.65
Mar 25	0.59
Mar 25	0.64
Feb 25	0.91
Feb 25	0.98
Feb 25	1.03
Feb 25	1.05
Jan 25	1.11
Jan 25	1.02
Jan 25	1.04
Jan 25	1.34
Jan 25	1.62
Dec 24	1.47
Dec 24	1.51
Dec 24	1.78
Dec 24	2.55
Nov 24	2.78
Feb 24	1.87
Feb 24	1.91
Feb 24	2.02
Feb 24	1.85
Jan 24	1.91
Jan 24	1.87

No video analysis for this stock yet. Request one from our team.

News: OKUR

globenewswire.com · 31 Aug 2026

OnKure Therapeutics to Participate in the Morgan Stanley Global Healthcare Conference

BOULDER, Colo., Aug. 31, 2026 (GLOBE NEWSWIRE) -- OnKure Therapeutics, Inc. (Nasdaq: OKUR), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines, today announced that senior management will participate in the upcoming Morgan Stanley 24th Annual Global Healthcare Conference being held in New York on September 14 – 16, 2026.

globenewswire.com · 4 Aug 2026

OnKure Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Highlights

-- Executing IND-enabling activities for next-generation PI3Kα pan-mutant selective candidates OKI-345 in breast cancer and OKI-355 in vascular anomalies, with IND submissions planned for 1H 2027

marketbeat.com · 15 Jul 2026

OnKure Therapeutics Spotlights Allosteric PI3Kα Drugs as 2027 IND Targets Near

OnKure Therapeutics NASDAQ: OKUR used a scientific webcast to outline its strategy for developing mutant-selective PI3Kα inhibitors, emphasizing allosteric inhibition as a potential way to improve efficacy and tolerability in cancer and vascular anomalies.

globenewswire.com · 2 Jul 2026

OnKure Therapeutics to Host Virtual KOL Event to Discuss PI3Kα Inhibitor Medicines: Selectivity Matters & Pan-Mutant Allosteric Inhibition Delivers, on July 15, 2026

BOULDER, Colo., July 02, 2026 (GLOBE NEWSWIRE) -- OnKure Therapeutics, Inc. (Nasdaq: OKUR), a clinical-stage biopharmaceutical company focused on developing novel precision medicines, today announced that it will host a virtual key opinion leader (KOL) event on Wednesday, July 15, 2026 at 11:00 AM ET featuring Benjamin F. Cravatt, PhD (The Scripps Research Institute) and Robert Abraham, PhD (Engine Biosciences). They will join company management to discuss the significance of PI3Kα selectivity and the Company's structure-based drug design approach for discovering allosteric pan-mutant PI3Kα inhibitors. To register, click here.